What is Liquid Biopsy?

Liquid autopsy is a test that analyzes blood samples to screen for cancer DNA shed by tumors into the bloodstream. When tumors grow and spread, they shed DNA, cells and other particles into the bloodstream. Liquid autopsy allows doctors to analyze these biological clues picked up from blood to detect early-stage cancer non-invasively. In contrast to traditional tissue biopsies that take tumor samples by surgery or invasive procedures, liquid autopsy is a simple blood test that can be done repeatedly with minimal risk to patients.

How does it work?

To perform a liquid autopsy, a blood sample is taken from the patient, usually from a vein in the arm. The blood is processed to isolate circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) or exosomes - tiny sacs released by tumors into blood. Advanced DNA sequencing techniques are then used to analyze these tumor-specific biomarkers and detect genetic mutations associated with different cancer types. By identifying tumor-specific genetic signatures in blood, liquid autopsy can detect the presence of cancer, track its progression over time and help guide treatment decisions.

Potential Benefits

Early Detection: Liquid autopsy allows cancer screening even before tumors are visible on scans. It can detect cancer at an earlier, more treatable stage by identifying tumor DNA in blood when the disease is still localized. This expands the pool of patients who could benefit from curative treatment options.

Non-invasive Monitoring: Liquid Biopsy is minimally invasive so it enables frequent monitoring of patients during and after cancer treatment. Repeated liquid biopsies allow doctors to track a tumor's genomic evolution in real-time and detect even small amounts of residual or recurring disease early through blood tests alone without invasive procedures.

Guiding Treatment: Analyzing circulating tumor biomarkers can provide information about mutations driving a patient's cancer. This molecular profiling helps guide treatment decisions such as choosing targeted therapies that inhibit specific cancer-causing gene mutations. Liquid autopsy also helps monitor treatment response and detect the emergence of new resistance mutations.

Challenges and Limitations

Sensitivity: One challenge is the test's relatively low sensitivity since only a small fraction of tumor DNA may be detected in early-stage cancers when circulating DNA levels are low. Improving detection sensitivity remains an area of active research and technology development.

Tissue Validation: Since liquid biopsies analyze blood-based biomarkers rather than tumor tissue samples directly, additional tissue biopsies may still be required to fully validate liquid autopsy test results, guide treatment selection, and comprehensively profile the tumor.

Clinical Utility: More evidence is still needed to demonstrate the clinical impact and utility of liquid autopsy results in prospectively guiding cancer management decisions and improving patient outcomes. Large clinical validation studies are underway to address this.

Cost and Accessibility: While costs have declined significantly, widespread clinical use also depends on addressing health economic aspects to make liquid autopsy an affordable and accessible routine cancer screening and monitoring tool globally.

Future Outlook

Despite current limitations, liquid autopsy shows enormous potential to revolutionize how cancer is detected, profiled and treated. Areas of active research include improving test sensitivity for early detection, profiling additional biomarker classes like CTCs and exosomes, multi-cancer screening panels, developing minimally-invasive techniques for tumor tissue extraction, and validating clinical utility through large prospective outcome studies.

Liquid biopsy could transform cancer patient management and help realize the promise of precision oncology. Already, an increasing number of liquid autopsy tests have been approved or are in late-stage clinical validation globally. As costs reduce further and technical capabilities advance, liquid autopsy is positioned to become a mainstream cancer monitoring and management tool worldwide in the near future.

Get more insights on Liquid Biopsy